Breast cancer is the second leading cause of cancer deaths in women in the US¹

Approximately 234,190 new breast cancer cases will be diagnosed in 2015¹

Approximately 40,730 people will die from breast cancer in 2015¹

Patients with a personal and/or family history of breast cancer may be at risk for hereditary cancer

Individuals with hereditary breast cancer may have an up to 60% risk of developing a second primary breast cancer.² Clinical research has validated that multiple genes can be associated with hereditary breast cancer. If you are using a narrow testing approach, you could be missing critical information necessary to manage you patients’ actual cancer risks. The best way to identify patients with hereditary breast cancer is with the Myriad myRisk pan-cancer panel.


Mutation Prevalence (n= 27,994 patients)

Mutation Prevalence in Patients with Breast Cancer


The wide spectrum of mutations present in this group of patients with breast cancer demonstrates the importance of using a pan-cancer panel testing strategy with Myriad myRisk.³

Data confirms the benefits of pan-cancer panel testing among patients at risk for hereditary breast cancer

A study by Sharma et al. presented at the European Society of Human Genetics (ESHG) annual conference on June 6th, 2015 analyzed the spectrum of mutations identified in nearly 28,000 patients with breast cancer. Only ~52% of mutations present were found in BRCA1 and BRCA2 and other high-penetrance genes associated with breast cancer (PTEN, TP53, CDH1, and STK11). An additional ~38% of the total mutations were found in moderate-penetrance genes also associated with breast cancer (PALB2, CHEK2, ATM, BRIP1, BARD1, and NBN).

However, the remaining 10% of mutations were found in genes not previously considered to be associated with breast cancer (MLH1, MSH2, MSH6, PMS2, EPCAM, APC, Biallelic MUTYH, CDK2NA, RAD51C, RAD51D, and SMAD4), all of which warrant consideration for medical management changes based on significant other cancer risks.3 In fact, patients with mutations in Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2, and EPCAM) have an up to 82% risk of developing colorectal cancer.4,5


For more information about the data presented by Sharma, please see the
data summary


Myriad myRisk identifies significantly more mutations across eight important cancer sites compared to syndrome-specific or cancer-specific testing.3,6,7


In fact, Myriad myRisk identifies more than twice the number of mutations in patients with breast cancer compared to syndrome-specific (BRCA1/BRCA2) testing.3

 

Myriad myRisk provides accurate results and clear management direction for patients with increased cancer risks

  • >99.9% confidence in test accuracy and variant interpretation8,9
  • Rapid turnaround time of 14-21 days for test results
  • myRisk Management Tool provides a summary of society guidelines to help optimize patient care and improve patient outcomes
  • Myriad Promise is a program for patients who encounter any financial hardship associated with their bill –Myriad will work directly with the patient toward their complete satisfaction, guaranteed


Be confident in knowing your patients’ comprehensive cancer risks and specific medical management options with the Myriad myRisk Hereditary Cancer Panel

Order a Myriad myRisk test kit Today


References

  1. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf
  2. http://www.cancer.net/cancer-types/hereditary-breast-and-ovarian-cancer
  3. Spectrum of Mutations Identified in a 25-gene Hereditary Cancer Panel for Patients with Breast Cancer, Sharma et. al. Presented at ESHG 2015
  4. Burt RW et al. NCCN Clinical Practice Guidelines in Oncology® Colorectal Cancer Screening. V 2.2013. July 1. Available at http://www.nccn.org.
  5. Kohlmann W, Gruber SB. Lynch syndrome. In: Pagon RA, et al., editors. GeneReviews. 2012 Available from http://www.ncbi.nlm.nih.gov/books/NBK1211. PMID: 20301390.
  6. Langer et al. A study of ovarian cancer patients tested with a 25-gene panel of hereditary cancer genes. Presented at ASCO June 2014
  7. Yurgelun et al. Multi-gene panel testing in patients suspected to have Lynch syndrome. Presented at ASCO June 2014.
  8. Roa et. al. Development of next generation sequencing panel to assess hereditary cancer risk that includes clinical diagnostic analysis of the BRCA1 and BRCA2 genes. Presented at ASHG in 2013
  9. Bowles et. al. A clinical history weighting algorithm accurately classifies BRCA1 and BRCA2 variants. Presented at ACMG in 2013

Leave a Reply

Your email address will not be published. Required fields are marked *